MedPath

Heparin Versus Normal Saline in Peripherally Inserted Central Catheter Lines

Early Phase 1
Completed
Conditions
Cancer
Interventions
Drug: Normal Saline Group
Registration Number
NCT05029596
Lead Sponsor
University of Texas Southwestern Medical Center
Brief Summary

The study team will be performing a study comparing the use of Heparin Flushes vs. Normal Saline Flushes in making sure central lines stay open. The participants will be placed in a group to receive the University of Texas Southwestern Medical Center (UTSW) Standard of Care (control group) for maintaining central lines, or a group to receive Normal Saline Flushes only (experimental group) to keep their central line open. The participants electronic medical record will be reviewed by study team members for the inclusion/exclusion criteria, the participants central line will be assessed by an 11 Blue BMT nurse every 12 hours, and they may be asked questions regarding their medical history during their stay on 11 Blue BMT. If a participant is discharged or transferred off of the 11 Blue BMT unit, they will no longer be included in the study and their central line maintenance will return to the UTSW Standard of Care. Participants in this study may be at risk for central line occlusion (a blood clot) which could require intervention to regain the free flow of fluids and use of the central line. The study team predicts there will be no increase in the rate of line occlusion when using Normal Saline Flushes only to maintain the free flow of fluids through participants central line. The study team also hopes the results of this study will help to improve patient outcomes by decreasing risk of infection, heparin associated complications, and costs.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
142
Inclusion Criteria
  • Oncology patients
  • Admitted to 11Blue Bone Marrow Transplant Unit at Clements University Hospital University of Texas Southwestern Medical Center
  • Ages 18-80 years
  • Pre-existing or newly placed PICC line
  • PICC line with good blood return (defined as: "brisk blood return of 3cc")
  • Flushes without difficulty
Exclusion Criteria
  • Patient less than 18 years of age or greater than 80 years of age
  • Refused or unable to give consent to the study
  • Patient admitted to the 11Blue BMT unit with any line other than a PICC line, or multiple lines
  • Patient admitted to 11Blue BMT for active transplant
  • Patient with a coagulopathy diagnosis
  • Patient on therapeutic dose of anticoagulants for documented Deep Vein Thrombosis or Pulmonary Embolism
  • Patient on inpatient hospice/comfort care
  • Patient transferred off 11B BMT unit onto another floor

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Normal Saline GroupNormal Saline GroupParticipants will receive only Normal Saline for PICC line maintenance. All lumens of PICC line will be flushed every 24 hours with 10cc Normal Saline. PICC line will be flushed with 10cc Normal Saline after administration of medication, blood products, or blood draws.
Heparin GroupHeparin GroupParticipants will receive the UTSW standard of of care for PICC line maintenance. All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
Primary Outcome Measures
NameTimeMethod
PatencyUp to Day 7 of enrollment

To determine whether or not flushing central lines with normal saline only will maintain free flow through these central lines.

Secondary Outcome Measures
NameTimeMethod
Infection RateFrom Day 1 and up to Day 7 of enrollment

To determine whether or not removing Heparin Flushes from PICC line maintenance decreases the risk for central line associated infections

Trial Locations

Locations (1)

Clements University Hospital

🇺🇸

Dallas, Texas, United States

Clements University Hospital
🇺🇸Dallas, Texas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.